论文部分内容阅读
CD137是肿瘤坏死因子受体(TNFR)家族成员之一,表达在活化T细胞、B细胞、NK1.1及活化的单核细胞表面上。活化细胞表面CD137与其配体结合后,介导的共刺激信号,是CD28/B7之外的另一重要的共刺激信号。CD137介导的协同刺激信号,可依赖或不依赖CD28途径发挥共刺激作用,调节T细胞、B细胞、单核细胞、NK1.1的活化、分化、增殖,提高免疫细胞的作用,阻止活化诱导的细胞的凋亡,在一定条件下具有抗肿瘤的作用和加速移植排斥反应。因此,CD137与其配体既参与机体免疫调节,又介导了免疫病理。CD137与其配体在不同的病人体内表达水平不一致,不仅影响机体的抗肿瘤作用,而且对肿瘤的发生、发展和预后具有重要意义。
CD137 is a member of the tumor necrosis factor receptor (TNFR) family and is expressed on the surface of activated T cells, B cells, NK1.1, and activated monocytes. After activating cell surface CD137 binds with its ligand, it mediates costimulatory signal, which is another important costimulatory signal besides CD28 / B7. CD137-mediated costimulatory signals, can play a co-stimulatory role with or without CD28 pathway, regulate the activation, differentiation and proliferation of T cells, B cells, monocytes, NK1.1, enhance the role of immune cells and prevent activation induction Of the cells apoptosis, under certain conditions with the role of anti-tumor and accelerate graft rejection. Therefore, CD137 and its ligand are both involved in immune regulation of the body and mediate immunopathology. CD137 and its ligand in different patients with different levels of expression, not only affect the body’s anti-tumor effect, but also on the occurrence of tumor, development and prognosis of great significance.